EGM
KROS icon

Engineers Gate Manager’s Keros Therapeutics KROS Stock Holding History

Engineers Gate Manager’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$131K Sell
12,215
-4,380
-26% -$48.8K ﹤0.01% 2034
2026
Q1 		$183K Sell
16,595
-45,774
-73% -$707K ﹤0.01% 1934
2025
Q4 		$1.27M Buy
62,369
+36,000
+137% +$632K 0.02% 921
2025
Q3 		$417K Buy
26,369
+14,332
+119% +$212K ﹤0.01% 1596
2025
Q2 		$161K Sell
12,037
-94,896
-89% -$1.28M ﹤0.01% 1932
2025
Q1 		$1.09M Buy
106,933
+6,916
+7% +$80.3K 0.02% 1017
2024
Q4 		$1.58M Buy
100,017
+60,348
+152% +$3.14M 0.03% 733
2024
Q3 		$2.3M Sell
39,669
-8,137
-17% -$402K 0.05% 593
2024
Q2 		$2.18M Buy
47,806
+15,347
+47% +$825K 0.05% 516
2024
Q1 		$2.15M Buy
+32,459
New +$1.92M 0.06% 456

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Engineers Gate Manager's KROS Position: Q2 2026 in Review

Engineers Gate Manager reduced its Keros Therapeutics (KROS) stake by 26% in Q2 2026, selling an estimated $48.8K and leaving 12,215 shares worth $131K. The position accounts for ﹤0.01% of the portfolio, ranked #2034.

Engineers Gate Manager first reported a position in KROS in Q1 2024 and has held it in 10 quarters since. The position peaked at $2.3M in Q3 2024. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Engineers Gate Manager held 12,215 shares of Keros Therapeutics worth $131K as of Q2 2026.
  • Engineers Gate Manager sold 4,380 Keros Therapeutics shares in Q2 2026, an estimated $48.8K.
  • Keros Therapeutics made up ﹤0.01% of Engineers Gate Manager's portfolio in Q2 2026, its #2034 holding.
  • Engineers Gate Manager first reported a position in Keros Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Engineers Gate Manager's Keros Therapeutics position peaked at $2.3M in Q3 2024.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.